NYOH patients who need documentation to confirm eligibility to receive the COVID-19 vaccine, visit our COVID-19 resource page to learn how.
Learn More

Clinical Trials & Research

Ph2 IMMU-132 met Solid Tumors

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)

Disease Types: Lung (Non Small Cell),&nbs

Available at: {clinical_trial_location backspace="7"}Ph2 IMMU-132 met Solid Tumors, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}

{clinical_trial_description}